Senior Research Scientist at Moffitt Cancer Center, United States
Dr. Jyoti Srivastava is a leading figure in Targeted Cancer Therapy, with extensive expertise in developing innovative approaches to cancer treatment. Her work in Targeted Cancer Therapy spans multiple cancer types, emphasizing molecular targets and mechanisms of resistance. By integrating Targeted Cancer Therapy strategies with tumor biology research, she has advanced personalized medicine approaches. Targeted Cancer Therapy under her leadership incorporates novel biomarkers, translational research, and immune-oncology concepts. Her contributions in Targeted Cancer Therapy include pioneering nitrosylation inhibition strategies, improving MEK inhibitor sensitivity, and designing effective molecular interventions. With a focus on Targeted Cancer Therapy for melanoma, liver cancer, and other malignancies, Dr. Srivastava’s vision is shaping the future of precision oncology through continuous Targeted Cancer Therapy innovation.
Professional Profile
ORCID Profile | Google Scholar Profile
Education
Dr. Jyoti Srivastava’s educational background is deeply rooted in molecular biology and biotechnology, forming a strong foundation for her Targeted Cancer Therapy expertise. She has applied her academic training to explore the complexities of tumor microenvironments, translating this knowledge into advanced Targeted Cancer Therapy approaches. Her studies in biological sciences have enabled her to understand the genetic, molecular, and biochemical pathways critical for effective Targeted Cancer Therapy. Dr. Srivastava’s education emphasized research excellence, laboratory skills, and data analysis, all vital for Targeted Cancer Therapy development. The integration of theoretical knowledge and practical applications has allowed her to innovate in Targeted Cancer Therapy strategies. By bridging fundamental science with applied oncology, she continues to transform her educational insights into groundbreaking Targeted Cancer Therapy solutions.
Experience
Dr. Jyoti Srivastava’s professional experience reflects a profound dedication to Targeted Cancer Therapy, spanning leadership roles in academia, pharmaceuticals, and research institutions. She has led multidisciplinary teams in Targeted Cancer Therapy projects addressing melanoma, hepatocellular carcinoma, and other cancers. Her expertise in Targeted Cancer Therapy includes molecular target identification, drug resistance mechanisms, and immune modulation. At major cancer centers and biotech companies, she has advanced Targeted Cancer Therapy pipelines from concept to preclinical validation. Her roles demanded integration of Targeted Cancer Therapy with molecular pharmacology, immunology, and translational science. These experiences in Targeted Cancer Therapy have established her as a trusted leader in the field, capable of delivering high-impact solutions for patients through innovative Targeted Cancer Therapy strategies.
Research Interest
Dr. Jyoti Srivastava’s research interests center on Targeted Cancer Therapy innovations that address resistance and improve patient outcomes. She investigates molecular pathways relevant to Targeted Cancer Therapy, such as nitrosylation, MEK/ERK signaling, and tumor immune evasion. Her Targeted Cancer Therapy research extends to novel biomarkers, therapeutic combinations, and personalized treatment approaches. By leveraging biochemical, genomic, and proteomic tools, she explores how to optimize Targeted Cancer Therapy in challenging cancer subtypes. She is particularly interested in applying Targeted Cancer Therapy to melanoma and liver cancers, aiming to enhance efficacy and minimize toxicity. Her commitment to advancing Targeted Cancer Therapy drives her to continually explore new targets, mechanisms, and delivery systems to maximize therapeutic impact.
Award and Honor
Dr. Jyoti Srivastava has earned numerous awards and honors recognizing her outstanding contributions to Targeted Cancer Therapy research. These accolades celebrate her pioneering work in Targeted Cancer Therapy, particularly her breakthroughs in melanoma and hepatocellular carcinoma treatment. She has been acknowledged by prestigious scientific societies for her Targeted Cancer Therapy innovations, editorial leadership, and impactful publications. Her awards reflect excellence in Targeted Cancer Therapy across research, mentorship, and scientific communication. Dr. Srivastava’s recognition reinforces her position as a leading authority in Targeted Cancer Therapy, inspiring peers and students alike. Each award symbolizes a milestone in her journey to refine Targeted Cancer Therapy strategies and develop patient-focused solutions that redefine modern cancer care.
Research Skill
Dr. Jyoti Srivastava possesses a wide range of research skills essential for advancing Targeted Cancer Therapy. Her technical expertise includes molecular biology, cell signaling, proteomics, and translational oncology, all applied within Targeted Cancer Therapy frameworks. She excels in designing experiments that dissect cancer pathways relevant to Targeted Cancer Therapy and in analyzing complex datasets for clinical application. Her proficiency in developing targeted agents, validating biomarkers, and integrating omics data strengthens her Targeted Cancer Therapy initiatives. She is skilled in team leadership, grant writing, and multidisciplinary collaboration, ensuring that Targeted Cancer Therapy projects are both scientifically robust and clinically relevant. These research skills empower her to translate fundamental discoveries into impactful Targeted Cancer Therapy solutions.
Publication Top Notes
Title: Increased RNA‐induced silencing complex (RISC) activity contributes to hepatocellular carcinoma
Authors: BK Yoo, PK Santhekadur, R Gredler, D Chen, L Emdad, S Bhutia, ...
Journal: Hepatology
Title: Multifunction protein staphylococcal nuclease domain containing 1 (SND1) promotes tumor angiogenesis in human hepatocellular carcinoma through novel pathway that involves …
Authors: PK Santhekadur, SK Das, R Gredler, D Chen, J Srivastava, C Robertson, ...
Journal: Journal of Biological Chemistry
Title: AEG-1/MTDH/Lyric: Clinical Significance
Authors: D Sarkar, PB Fisher
Journal: Advances in Cancer Research
Title: Astrocyte elevated gene-1 promotes hepatocarcinogenesis: novel insights from a mouse model
Authors: J Srivastava, A Siddiq, L Emdad, PK Santhekadur, D Chen, R Gredler, ...
Journal: Hepatology
Title: Staphylococcal nuclease domain containing-1 (SND1) promotes migration and invasion via angiotensin II type 1 receptor (AT1R) and TGFβ signaling
Authors: PK Santhekadur, M Akiel, L Emdad, R Gredler, J Srivastava, ...
Journal: FEBS Open Bio
Title: Role of the staphylococcal nuclease and tudor domain containing 1 in oncogenesis
Authors: N Jariwala, D Rajasekaran, J Srivastava, R Gredler, MA Akiel, ...
Journal: International Journal of Oncology
Title: AEG-1/MTDH/LYRIC, the beginning: initial cloning, structure, expression profile, and regulation of expression
Authors: SG Lee, DC Kang, R DeSalle, D Sarkar, PB Fisher
Journal: Advances in Cancer Research
Title: Genetic deletion of AEG-1 prevents hepatocarcinogenesis
Authors: CL Robertson, J Srivastava, A Siddiq, R Gredler, L Emdad, ...
Journal: Cancer Research
Title: Combination of Nanoparticle-Delivered siRNA for Astrocyte Elevated Gene-1 (AEG-1) and All-trans Retinoic Acid (ATRA): An Effective Therapeutic Strategy for …
Authors: D Rajasekaran, J Srivastava, K Ebeid, R Gredler, M Akiel, N Jariwala, ...
Journal: Bioconjugate Chemistry
Title: AEG-1 regulates retinoid X receptor and inhibits retinoid signaling
Authors: J Srivastava, CL Robertson, D Rajasekaran, R Gredler, A Siddiq, ...
Journal: Cancer Research
Conclusion
Dr. Jyoti Srivastava’s career exemplifies excellence in Targeted Cancer Therapy, blending rigorous science with innovative clinical vision. Her journey in Targeted Cancer Therapy reflects dedication to improving patient outcomes through targeted, personalized approaches. She has consistently advanced the frontiers of Targeted Cancer Therapy by identifying novel targets, overcoming resistance, and integrating multidisciplinary methods. Through her research, leadership, and publications, she continues to shape the field of Targeted Cancer Therapy, inspiring collaboration and innovation. Her commitment to translating laboratory discoveries into patient-centered solutions ensures that Targeted Cancer Therapy remains at the forefront of cancer treatment strategies. Dr. Srivastava’s legacy will be defined by her transformative contributions to Targeted Cancer Therapy.